Apogee Therapeutics, Inc. Common Stock (APGE NASDAQ) stock market data APIs
$70.6047
0.91(1.3%)
as of March 5, 2026
Try our APIs with
free plan!
Apogee Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Prev. Close
70.6047
Open
71.5157
High
72.7761
Low
68.7058
52 wk Range
26.2-84.56
Market Cap
4 940 M
Shares Outstanding
54 834 K
EPS
-1.03
Beta
1.399
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Apogee Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apogee Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Apogee Therapeutics, Inc. Common Stock Fundamental Data
Apogee Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -284 176 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-10
- EPS/Forecast: -0.62
Get Apogee Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apogee Therapeutics, Inc. Common Stock News
New
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened Acco...
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Ha...
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)?
Apogee Therapeutics recently reported a higher full-year 2025 net loss of US$255.84 million and a wider basic loss per share, while also filing a US$287.29 million common stock shelf registration and ...
Apogee Therapeutics Posts Wider FY25 Loss, Advances Zumilokibart Pipeline
(RTTNews) - Apogee Therapeutics, Inc. (APGE) has reported full-year 2025 financial results alongside significant progress across its pipeline, led by Zumilokibart. For the year ended December 31, 2025...
Get Apogee Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
